{"id":627058,"date":"2025-12-11T21:44:14","date_gmt":"2025-12-11T21:44:14","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/627058\/"},"modified":"2025-12-11T21:44:14","modified_gmt":"2025-12-11T21:44:14","slug":"europe-must-get-its-act-together-to-regain-global-competitiveness-industry-says-politico","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/627058\/","title":{"rendered":"Europe must get its act together to regain global competitiveness, industry says \u2013 POLITICO"},"content":{"rendered":"<p>But there is hope \u2014 both for the pharmaceutical industry and beyond. Per Franz\u00e9n, CEO and managing partner at EQT, a global investment organization, said he is seeing \u201can unprecedented interest to invest into Europe.\u201d<\/p>\n<p>&#8220;It\u2019s a real window of opportunity, a unique moment in time for Europe,&#8221; he said. &#8220;In order to make the most out of that opportunity, what we need to do is really to drive a more business-friendly, more innovation-friendly agenda,&#8221; he said. But with the pace of change, driven by artificial intelligence, &#8220;time is of the essence,&#8221; he added.<\/p>\n<p>Over-regulation isn&#8217;t holding Europe back in medicines innovation, it&#8217;s a lack of substantial incentives for companies to invest in Europe, Oelrich said.<\/p>\n<p><video controls=\"\" src=\"https:\/\/www.politico.eu\/wp-content\/uploads\/2025\/12\/11\/GET-OUR-ACT-TOGETHER.mp4\"\/><\/p>\n<p>But it doesn\u2019t have to be this way, he said: \u201cWe have some of the best universities in the world that publish some of the coolest science in the world. So there is no reason why this wouldn&#8217;t work. And we need to get our act together,\u201d he said.<\/p>\n<p>\u201cInstead of trying to complicate our lives and come up with a new bureaucratic idea, we should come up with with ways of how we unleash our forces.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"But there is hope \u2014 both for the pharmaceutical industry and beyond. Per Franz\u00e9n, CEO and managing partner&hellip;\n","protected":false},"author":2,"featured_media":627059,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5174],"tags":[194449,74019,2000,6562,299,5187,1197,5769,194448,10057,2443,194447],"class_list":{"0":"post-627058","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu","8":"tag-bayer-ag","9":"tag-biotech-drugs","10":"tag-eu","11":"tag-eu27","12":"tag-europe","13":"tag-european","14":"tag-investment","15":"tag-medicines","16":"tag-member-of-the-board-of-management-and-president-of-the-pharmaceuticals-division","17":"tag-pharma","18":"tag-regulation","19":"tag-stefan-oelrich"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115703124224686578","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/627058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=627058"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/627058\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/627059"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=627058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=627058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=627058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}